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SUMMARY 
The polo kinase family are important oncology targets that act in regulating entry into and 
progression through mitosis. Structure-guided discovery of a new class of inhibitors of Polo-
like kinase 1 (PLK1) catalytic activity that interact with Cys67 of the ATP binding site is 
described. Compounds containing the benzothiazole N-oxide scaffold not only bind 
covalently to this residue, but are reversible inhibitors through the formation of 
Meisenheimer complexes. This mechanism of kinase inhibition results in compounds that can 
target PLK1 with high selectivity, while avoiding issues with irreversible covalent binding 
and interaction with other thiol-containing molecules in the cell. Due to renewed interest in 
covalent drugs and the plethora of potential drug targets, these represent prototypes for the 
design of kinase inhibitory compounds that achieve high specificity through covalent 
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interaction and yet still bind reversibly to the ATP cleft, a strategy that could be applied to 
avoid issues with conventional covalent binders. 
 
INTRODUCTION 
The Polo-like kinases (PLKs) are serine/threonine protein kinases that are key regulators of 
the cell cycle, and in mammals have been reported to play numerous roles in regulating entry 
into and progression through mitosis (Craig et al., 2014; McInnes and Wyatt, 2011). PLK1 is 
expressed throughout the cell cycle, although its activity peaks late in G2 and is sustained 
through mitosis (Hamanaka et al., 1995; Lee et al., 1995). At the end of G2, through 
phosphorylation and promotion of nuclear translocation (Toyoshima-Morimoto et al., 2002), 
PLK1 acts on CDC25C (Roshak et al., 2000), resulting in activation of CDK1/cyclin B by 
removal of inhibitory phosphate groups (Nurse, 1990). PLK1 also promotes sister chromatid 
separation mediated by activation of the APC (Golan et al., 2002; Kotani et al., 1998), and 
also through phosphorylation of the SCC1 subunit of cohesin (Alexandru et al., 2001; Sumara 
et al., 2004). Mitotic exit occurs after PLK1 interacts with and phosphorylates the kinesin-
like protein, CHO1/MKLP-1 and promotes cytokinesis (Lee et al., 1995). Four closely related 
PLKs exist in humans (Glover et al., 1998) and structurally contain two separate, highly 
homologous domains: an amino-terminal region that contains the catalytic kinase domain and 
a C-terminal domain that has two conserved Polo-box regions (Elia et al., 2003a, 2003b) (one 
in PLK4 [Leung et al., 2002]). A fifth PLK has been identified but shown to lack a kinase 
domain (de Carcer et al., 2011). The polo boxes function in recruitment for subcellular 
localization and compartmentalization (Lee et al., 1998). Furthermore there is evidence 
suggesting that the Polo-box domain (PBD) participates in regulating interactions with 
substrates, e.g., CDC25C phosphatase (Elia et al., 2003a, 2003b), as an autoregulatory 
domain (Jang et al., 2002). Furthermore, PBD-dependent PLK1 activity is required for proper 
metaphase/anaphase transition and cytokinesis (Seong et al., 2002; Yuan et al., 2011). 
Overexpression of PLK1 is a common occurrence in cancer and is of prognostic value for 
several tumor types (Knecht et al., 1999; Takahashi et al., 2003; Tokumitsu et al., 1999; Wolf 
et al., 1997; Yuan et al., 1997). In addition, constitutive expression of PLK1 in mammalian 
cells can lead to malignant transformation (Smith et al., 1997). PLK1 has been extensively 
validated as an anti-tumor drug target using a variety of cellular and in vivo studies. 
Downregulation of PLK1 activity, through the administration of antisense oligonucleotides 
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and small interfering RNA molecules, has been demonstrated to be highly effective in 
inhibition of proliferation of cancer cells both in vitro and in vivo (Elez et al., 2000, 2003; 
Spankuch-Schmitt et al., 2002a, 2002b). Several drug candidates have been investigated in 
human trials including BI2536 and GSK461364A, with the most advanced compound being 
volasertib (BI-6727), shown to have clinical efficacy in combination with cytarabine in acute 
myeloid leukemia (Dohner et al., 2014; Gjertsen and Schoffski, 2014). Although promising 
activity has been observed, there is continued scope to improve clinical outcomes through 
optimization of mechanism of inhibition and pharmacokinetic and dynamic properties. 
Here a structure-guided design approach to the discovery and development of benzothiazole 
N-oxide PLK1 inhibitors is described. These highly selective molecules inhibit the enzyme 
through a covalent but reversible mechanism involving a Meisenheimer complex (MC), 
which is without precedent in the protein kinase literature. In recent years, covalent inhibition 
of drug targets, and especially of protein kinases, has been recognized as an effective 
approach to improving selectivity and for overcoming drug resistance; however, this is not 
without significant issues including potential toxicities (Baillie, 2016). Inhibition through MC 
formation is a promising strategy to combine the benefits of a covalent mechanism while 
retaining reversible binding to the drug target of interest. A recent report described the 
observation of a MC in the context of nitrobenzothiazinone anti-tuberculosis drugs; however, 
it did not elaborate these as contributing to potency and selectivity but merely from the 
standpoint of the metabolic implications for continuing development of this important class 
of drugs (Kloss et al., 2017). The compounds described herein therefore represent prototypes 
and proof of concept for exploiting the MC in kinase inhibition and potentially more broadly 
in drug discovery. 
 
RESULTS 
PLK1 Is Irreversibly and Selectively Inhibited by Thiol Modifying Agents 
A structure-guided approach for the discovery of the cyclapolin benzothiazole N-oxide class 
of inhibitors has been described (McInnes et al., 2006). This approach preceded the 
determination of the crystal structure of PLK1 kinase domain. Upon construction of a 
homology structure and examination of the ATP binding site residues, it was observed that 
PLK1 had some unusual features compared with other protein kinases. In particular, the 
residue at the end of the glycine-rich loop that commonly interacts with the ribose of ATP, 
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and is frequently a valine, occurs as a cysteine in PLK1 (C67). This residue in other protein 
kinase-ligand crystal structures generally makes significant contacts with ATP competitive 
small molecules (e.g., V18 in CDK2). The unique characteristic of C67 in PLK1 thus could 
allow exploitation of the nucleophilicity of the thiol side chain to enable covalent binding of 
PLK1 inhibitors. 
The development of irreversible kinase inhibitors has precedent in the literature in the context 
of the epidermal growth factor receptor tyrosine kinases, where non-covalently binding ATP 
competitive compounds were converted by addition of a geometrically appropriate reactive 
functionality (Singh et al., 1997). These compounds were designed to form a covalent bond 
with a cysteine in the kinase active site and thus to take advantage of the thiol attack on the 
inhibitor. In the erbB1 kinase domain, 2’-thioadenosine (2TA), 1 (Figure 1), places the thiol 
adjacent to the C833 and was shown in this to form a disulfide bond and to inhibit the kinase 
activity. As the active site cysteine (C67) is on the opposite face of the ATP cleft in the PLK1 
context, inhibition would necessitate the synthesis of 5’-thioadenosine (5TA), 2, (Figure 1) so 
as to position the ribose thiol proximal to the reactive side chain. Flexible docking of 5TA 2, 
with PLK1 was completed and the binding mode was verified through comparison with ATP 
bound crystal structures. Further to this, the disulfide link between C67 and 5TA 2, was 
formed in silico and resulted in a conformation (Figure 2) similar to the experimental binding 
mode observed in other kinases. Subsequent to this, 2 was synthesized and shown to inhibit 
PLK1 kinase activity with a half maximal inhibitory concentration (IC50) of 39 µM. 2TA 1, 
exhibited markedly lower inhibition (120 µM) and adenosine 3 (Figure 1), itself had no 
observed activity against PLK1 (>200 µM). 
 
Discovery of Potent and Selective Inhibitors of PLK1 Using Lidaeus 
The homology model of the kinase domain of PLK1 was validated through the observed 
correlation of intermolecular contacts and binding energies of known inhibitors and through 
the assay results obtained from the use of thiol-modifying agents. Since it was considered to 
be of sufficient computational reliability, the model structure was further used in high-
throughput docking calculations to identify novel PLK1 starting points. To carry out this task, 
one of the previously docked thiazole anilino-pyrimidine compounds in complex with PLK1 
was used as a template structure for Lidaeus calculations. Lidaeus (Taylor et al., 2008; Wu et 
al., 2003), a tool for rapid flexible docking of ligands into protein binding sites, generates site 
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points from energies of probe atoms within a specified radius of the inhibitor. Interatomic 
ligand vectors are then matched with the site points from fragments of the molecule followed 
by positioning of subsequent fragments and ranking by overall intermolecular energy score. 
As previously described, using the complex of a pyrimidine derivative with PLK1, Lidaeus 
was employed to dock approximately 200,000 commercially available small molecules. From 
these, 350 in-silico-ranked compounds were assayed for PLK1 inhibition in a radiometric 
kinase assay quantifying the amount of radiolabeled ATP incorporated into the CDC25C 
substrate. A number of in vitro PLK1 inhibitors emerged from this strategy with an overall 
hit rate of 1% and a potency range of 0.5–20 µM IC50. While several confirmed hits were 
obtained, one series had more potent activity in the kinase assay and consisted of a 
benzothiazole N-oxide core structure. The obtained hit, 4 (Table 1), was promising not only 
from its micromolar potency but also from its low molecular weight and potential for 
synthesizing a number of derivatives that could optimize potency and drug-like properties. 
The phenotypic activity of compound 4 has previously been described where novel roles of 
PLK1 in spindle pole maintenance were demonstrated through use of this molecule as a 
chemical biology probe (McInnes et al., 2006). The structure-activity relationship of 4 and its 
related analogs are described for the first time in the following results. 
 
Structure-Activity Relationship Determination of Benzothiazole Inhibitors 
Subsequent to the identification of 4 as a potent PLK1 inhibitor, a set of commercial 
compounds expanding on the benzothiazole N-oxide scaffold were obtained and tested for 
inhibition of PLK1. This included a significant number of secondary amide and ester 
derivatives at the R3 position of the thiazole ring. Surprisingly none of these compounds 
exhibited any significant level of in vitro inhibition of PLK1, thus suggesting an important 
contribution of the primary amide (see structure in Table 1, inactive esters not shown) to 
binding. 
To further explore the structure-activity relationship (SAR) of this series, a synthetic route for 
the benzothiazole N-oxide was developed, and a number of analogs related to the in silico hit 
compound were prepared. Firstly, the substituents on the aryl component of the 
pharmacophore were modified, and testing of these compounds in the PLK1 assay yielded 
information on the SAR. A number of derivatives were synthesized (Table 1) replacing the 
CF3 with other groups and included fluoro 5, iodo 6, methyl ester 7, nitrile 8, and methyl 9. 
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Surprisingly, only compounds possessing electron-withdrawing substituents in this position 
exhibited activity against PLK1. In particular, the methyl group derivative 9, which is 
isosteric with CF3, was completely inactive. When the CF3 group in the in-silico-discovered 
compound was replaced with a trifluoromethyl-thioether 10, an increase in potency was 
observed. This compound increased in potency from 2.5 to approximately 0.4 µM, suggesting 
that the spacing functionality resulted in more complementary interactions of the CF3 group 
in the ATP binding site. Generation of the free carboxylate group from hydrolysis of the 
methyl ester 7, to generate compound 11, interestingly resulted in an inactive molecule. 
Further synthetic modification of the substituents on the thiazole ring were carried out and 
revealed that the incorporation of other small polar groups replacing the amide resulted in 
active compounds, although none as potent as the parent hit (Table 1). Compounds tested 
included those with nitrile 12, hydroxamate 13, and hydrazide 16 functions. 
An additional observation made was that closely related compounds lacking the N-oxide on 
the thiazole ring were completely devoid of activity as exemplified by the reduction of the N-
oxide in 4 to generate 14 and that of the reduction of 10 to its counterpart (data not shown). 
These results were not in line with the predicted small contribution of a single atom to 
intermolecular binding but pointed to the importance of the electrostatic nature and electron-
withdrawing potential of the N-oxide functionality. Further SAR for the benzothiazole N-
oxide series was established through the synthesis of compound 15 with the CF3 and nitro 
groups reversed. This compound was surprisingly inactive pointing to essential interactions 
of the nitro group with the ATP binding site of PLK1. 
To gain some insight into the binding of the benzothiazole N-oxide lead compounds in the 
PLK1 ATP cleft, and to assess the contributions of various substituents for binding, 
molecular docking experiments were carried out using the PLK1 model structure and 
subsequently with the available crystal structures. Using this approach, numerous docking 
solutions were evaluated in terms of interaction energy, docking score, and, with respect to 
consistency, with known kinase inhibitory interactions. Particular attention was paid to the 
observed requirement for a primary amide group on the thiazole. A binding mode that 
fulfilled each of these criteria was observed (Figure 3). Interestingly, C67 is in close proximity 
to the C4 (aromatic ring) of the benzothiazole system, although it does not make the 
complementarity expected from the valine residue that is commonly found in this position. In 
addition, the interactions observed in the docked structure provided a clear rationale for CF3S 
group. These calculations indicate that the CF3S projects into a subpocket and shows a high 
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degree of complementarity with this region. A good correlation was observed between the 
non-bonded docking score and the potency of the inhibitors. 
 
Benzothiazole N-Oxide Inhibitors Interact Covalently with the PLK1 Active Site 
To confirm that the benzothiazoles were binding to the ATP cleft of PLK1 and were not 
targeting substrate binding or possibly another site resulting in allosteric inhibition of ATP 
binding, the Km,ATP was determined at various inhibitor concentrations. This measurement 
was repeated for two of the most potent PLK1 inhibitory compounds, 4 and 10. While 
compound 4 (2.5 µM IC50) was shown to be ATP competitive, as demonstrated by the 
variation in the Km for ATP, the significantly more potent analog, 10 was found to have 
similar Km for ATP at every ligand concentration studied (Figure 4). These data indicate that 
the equilibrium of binding for compound 10 shifts toward being non-ATP competitive in 
contrast to inhibitor 4. In light of these results, observation of the C67 side chain in the PLK1 
model structure and the outcomes of using thiol modifying agents, it was hypothesized that 
these compounds may be interacting covalently with the cysteine. Further investigation into 
the chemistry of the benzothiazole N-oxide series suggested a literature precedent for 
reactivity and susceptibility to nucleophilic attack on the aromatic ring (Bunting, 1979). This 
reaction has been shown to occur ortho or para to a nitro-substituted phenyl ring, where a 
covalent intermediate is formed as per the mechanism shown above Table 2, and has been 
named the ‘‘Meisenheimer complex.’’ 
Examination of the docked structure of 4 with the PLK1 model structure indicates a close 
proximity of the thiol of C67 and the C4 aromatic carbon (para to the nitro group and 
highlighted in Figure 3), and hence strongly supports this hypothesis. Confirmation of the 
MC was indicated through a set of model 1H nuclear magnetic resonance (NMR) experiments 
with the active and inactive compounds from the benzothiazole series. Addition of n-
butylamine as a surrogate nucleophile to the active compounds including 4, 7, 8, and 10, in 
each case, resulted in a dramatic color change of the compound in solution. For solubility 
purposes, all of these experiments relied on the use of the ethyl ester derivatives of each 
benzothiazole (R3 = CO2Et) dissolved in deuterated chloroform, and therefore the majority of 
model reactions were carried out using n-butylamine. Experiments were also undertaken with 
sodium 1-butanethiolate and showed similar dramatic changes in the color of the compound 
solution and in the UV spectrum (Figures S1 and S2). The requirement for polar aprotic 
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NMR solvents (potentially reactive) to solubilize the 1-butanethiolate precluded NMR 
experiments with this more appropriate model nucleophile. On the other hand, non-polar 
solvents did not allow NMR study of the MC due to a lack of compound solubility. 
Further experiments utilizing UV-vis spectrophotometry were carried out to support this 
hypothesis using ethanol as the solvent of choice. During initial experiments to identify the 
presence of the MC, it was observed that highly colored solutions were obtained upon 
addition of the model nucleophile (n-butylamine) to the benzothiazole N-oxide inhibitor, an 
observation consistent with the literature, where a red shift in the UV-vis spectrum is seen for 
λmax (Taylor, 1970). An extensive UV-vis spectrophotometric characterization of the series of 
active and inactive benzothiazoles was subsequently carried out to examine if a relationship 
existed between the induced color change and potency of the pharmacophoric series (Table 
2). It was determined that, for each of the active PLK1 inhibitors from this series, a 
substantial shift in UV absorbance was identified, accompanied by a dramatic increase in 
extinction coefficient for the new signal. Out of eight compounds tested, all six analogs with 
measurable IC50 values against PLK1 exhibited a significant UV shift and an enhancement of 
extent of absorbance. Conversely, neither of the inactive molecules in the series displayed 
either a UV shift or an increase in extinction coefficient (9a and 11a). In addition, a rough 
correlation of the increase in absorbance and potency of the compounds can be extracted 
from the measured data. Furthermore two additional inactive compounds in this series were 
tested and no UV shift or absorbance increase was observed (data not shown). 
Further characterization of the 1H NMR spectra of the inhibitors before and after addition of 
the nucleophile (n-butylamine) resulted in a disappearance of both the aromatic protons in the 
spectrum (Table 2) and a shift of the signals further upfield, which is characteristic of the 
cyclohexa-2,5-dien-1-ylidene azinate structure formed after nucleophilic attack (see above 
Table 2). Subsequent examination of the inactive compounds in a similar experimental 
protocol determined that for these benzothiazoles, no change in the aromatic 1H NMR signals 
occurred. This was shown to be true for the previous incongruously inactive compounds, 
including the CF3 to CH3 replacement, 9, and the carboxylate derivative, 11. Analysis of the 
compounds (those active against PLK1) recovered after removal of the n-butylamine showed 
that there was no evidence of the Meisenheimer adduct therefore confirming that this is a 
fully reversible reaction. 
 
 9 
Activity of Compound 4 and volasertib (BI6727) against PLK1 WT and PLK1 C67S 
To confirm whether C67 plays a role in the activity of the benzothiazole N-oxide series, as 
strongly suggested by the SAR data, along with the enzyme kinetics and spectroscopy results, 
compound 4 was investigated along with volasertib (BI6727), a potent PLK1 ATP inhibitor 
currently approved by the US Food and Drug Administration for the treatment of acute 
myeloid leukemia. Due to requirements for commercial assay screening, these compounds 
were tested against the wild-type PLK1 with a lower ATP concentration than previously used 
and shown to have IC50 values of 0.463 and 0.016 µM, respectively. Subsequent to this, a 
mutant PLK1 enzyme possessing the exchange of cysteine 67 for serine, was generated. As 
serine is considerably less nucleophilic than the native cysteine residue, it would not be 
expected to form the MC to a significant degree and therefore the activity of the 
benzothiazole N-oxide series should be dramatically lower in the context of this mutant. 
Testing of volasertib in the first instance showed that while its activity against PLK1 C67S 
was reduced compared with the wild-type, an IC50 of 0.151 µM was obtained (Figure 5). 
Staurosporine was also shown to potently inhibit PLK1 C67S (Figure S3). This contrasted to 
compound 4, which was found to be completely inactive at concentrations of >100 µM, 
thereby providing confirmation that Cys67 forms a covalent MC with the benzothiazole N-
oxide series as strongly suggested by the previously described data. 
 
Kinase Selectivity and Cellular Activity of Lead Inhibitors 
Since specificity can be problematic in the development of ATP competitive inhibitors of any 
protein kinase, the benzothiazole N-oxide series was tested on a panel of in-house enzymes 
(Table S1). Interestingly none of these were inhibited by the in-silico-identified lead 
compound 4. To further probe the selectivity of this compound, a further 20 kinases available 
from an out-sourced screen were examined for inhibition in the presence of 100 µM of 4, and 
included three kinases with a cysteine in the position equivalent to PLK1 (Table S2). None of 
this additional panel exhibited a significant level of inhibition, with the exception of CSK, 
whose activity was slightly blocked by the action of this compound (<50% inhibition at 100 
µM compound). Due to the level of potency obtained for this fragment like series, and the 
high degree of selectivity observed, it is apparent that the specificity arises from the 
demonstrated mechanism of inhibition through the MC. The selectivity of the most potent 
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inhibitor, 10, was also examined by testing against an in-house kinase panel and confirmed 
its selectivity toward PLK1. 
 
DISCUSSION 
The results presented here demonstrate that an approach to generating PLK1 inhibitors 
involving homology modeling, molecular docking of known ligands, and in vitro testing has 
determined novel features of the PLK1 ATP binding site that can be exploited in the 
structure-guided design of compounds specific for this kinase. The ability to selectively 
inhibit PLK1 via covalent interaction with C67 of the ATP binding site was confirmed 
through the synthesis of thio-adenosine derivatives (1 and 2). The cysteine is located on the 
glycine-rich loop in the N-lobe region in the position occupied by a valine in the majority of 
protein kinases and is quite unique to the PLKs. The preferential inhibition of PLK1 by 5TA, 
2, which, according to known kinase-ATP structures and subsequent modeling (Figure 2) in 
the PLK1 context, results from proximity of the thiol group to the reactive cysteine (as 
opposed to the 2’-thio derivative, where the thiol group projects toward the C-lobe and 
therefore would be less able to react with C67). Although 2TA, 1, inhibits PLK1 to a certain 
degree, its observed activity probably results from the flexibility of the ribose in the ATP 
binding site, enabling reaction with the cysteine residue. In addition, the observation that 
adenosine does not inhibit PLK1 gives weight to the hypothesis that selective covalently 
interacting inhibitors can be designed and synthesized based on the structural information 
obtained from this approach. These results, taken as a whole, strongly suggest that the 
cysteine residue present in the PLK1 ATP cleft can form covalent interactions with 
appropriately positioned electrophilic groups in an inhibitor. This novel feature of PLK1 
should thus enable the discovery and design of inhibitors that potently and selectively inhibit 
the activity of PLKs. To this end, as the homology structure was extensively validated, it was 
confidently utilized for database searching for new PLK1 inhibitors and resulted in the 
identification of the benzothiazole N-oxide pharmacophore. Results show that potency and 
selectivity for PLK1 over many other kinases can be achieved through this chemical series, 
which not only binds avidly to the active site but also interacts covalently with C67. While the 
homology structure was used in initial studies to propose the covalent mechanism of 
inhibition and for discovery of the benzothiazole N-oxide inhibitors, the publication of 
multiple crystal structures of the PLK1 kinase domain confirmed the position of C67 and 
further validated the results obtained with the homology structure. Furthermore, compounds 
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were redocked with PLK1 crystal structures and, as expected, also found to have binding 
modes compatible with formation of the MC. 
It is apparent from these results that the necessity for an electron-withdrawing group on the 
phenyl substituent of the benzothiazole, and the presence of the N-oxide for PLK1 inhibition, 
relate to the ability of these compounds to form MCs. This was determined by demonstrating 
a correlation between inhibitors of the benzothiazole series that show activity against PLK1 
and their ability to induce spectroscopic changes upon addition of a model nucleophile. This 
was further supported by the requirement of the R1 position (see Table 1) to be an electron-
withdrawing substituent. Small changes in the chemical structure of this series (i.e., 
replacement with isosteric groups, e.g., CF3 to CH3 or removal of the N-oxide functionality), 
which should not be so detrimental to kinase activity, resulted in complete lack of PLK1 
inhibition. These changes do not significantly alter the steric nature of the inhibitor, but 
would dramatically change the electronic nature of the structures. Increasing the electron-
withdrawing character at R1 would therefore make the C4 and C6 positions of the nitro-
substituted benzothiazole ring less electron-rich and more susceptible to nucleophilic attack, 
resulting in formation of the MC (see above Table 2). This was corroborated by the observed 
correlations that exist between the electronegativity of the R1 and R2 groups and the inhibitor 
potency, and also between the UV absorbance of the Meisenheimer adduct and the PLK1 
activity. 
The higher potency of compound 10 and the differing kinetics versus 4 (Figure 4.) can be 
explained by the greater affinity and complementarity of the SCF3 group with the PLK1 ATP 
binding site and the structural basis for this potency increase has been determined 
computationally. The SCF3 group has almost twice the lipophilicity of the CF3 group and 
therefore has greater potential to interact through van der Waals interactions in a binding 
pocket (Feng et al., 2016). Calculations show that the SCF3 of 10 has a significantly higher 
degree of complementarity with a sub-pocket of the ATP binding site compared with CF3 (4), 
occupying it almost completely and therefore explaining the potency increase in these terms 
alone (the significantly increased interactions of the SCF3 group are shown comparatively; 
Figure S4). As a result and consistent with enzyme inhibition kinetics, it is known that, if the 
affinity is tight enough, compounds can display non-competitive behavior. The kinetic 
differences of 4 versus 10 can be explained by the increased potency of 10, which results in 
stabilization of the binding mode and therefore, by extension, the covalent MC (Table 1). 
Other explanations such as displacement of the SCF3 group or differences in the oxidation of 
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the two compounds are very unlikely due to the similar electronegativities of the CF3 and 
SCF3 groups, and also the restrictions on the nucleophilic aromatic substitution reaction 
(SNAr) in this system. 
The lack of inhibition of the carboxylate derivative 11, despite possessing an electron-
withdrawing substituent most probably results from delocalization of the negative charge into 
the aromatic ring thus disfavoring nucleophilic attack. This was supported by the observation 
that this compound was refractory to formation of the MC, as demonstrated by the described 
spectroscopic methods. Reversal of the CF3 and NO2 groups of 4 to generate compound 15 
resulted in complete loss of activity on PLK1, an effect probably due to the critical nature of 
the nitro function to direct binding, and supported by electrostatic interactions with K82 in the 
docked structures (Figure 3). Since the nitro group is acting as an electron sink it will be 
more negatively charged in the MC and therefore contributes significantly to the enthalpy of 
binding. 
Confirmation for the MC formation and the resulting covalent inhibition of PLK1 through 
C67 was obtained through comparison of the activities of compound 4 and volasertib 
(BI6727) in inhibiting the wild-type PLK1 versus the C67S mutant. The retention of potent 
activity of volasertib for the mutant PLK1 and the complete loss of inhibition of 4 in this 
context provides strong evidence that the benzothiazole N-oxide series act through MC 
formation. The decreased activity of volasertib with PLK1 C67S is most likely due to the loss 
of van der Waals contacts in the context of the serine as the oxygen has a significantly 
smaller atomic radius than the sulfur. 
The formation of the Meisenheimer adduct between the benzothiazole ring and the sulfur 
nucleophile leads to high-affinity binding of this series and is likely responsible for the 
selectivity for PLK1 versus all of the other enzymes tested. This method of kinase inhibition 
is currently without precedent in the literature, and has been demonstrated to be a paradigm 
through which selective kinase inhibitors can be obtained. Despite the observation that these 
act through covalent bond formation with the reactive cysteine in the PLK1 active site, this 
series should not suffer from reactivity with general nucleophilic groups in biological milieu 
since the MC is not a stable intermediate and is under normal conditions fully reversible. This 
was demonstrated in the context of the benzothiazole N-oxide series in that no stable 
intermediate MC could be isolated after addition of model nucleophiles even though the 
presence of this species was confirmed using two spectroscopic methods. 
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In addition to the experimental methods used and which confirmed the mechanism of 
inhibition of the benzothiazole series through the MC, the molecular docking calculations 
that were carried out strongly support the proposed covalent interaction with C67. The binding 
modes and interaction energetics generated using a rigorous molecular mechanics docking 
approach (allowing flexibility of both the ligand and ATP binding site residues) were 
predicted for a set of the active analogs. As the SAR data pointed to the critical nature of the 
primary amide group, and since a frequent binding determinant of kinase inhibitors includes 
an H-bond donor and acceptor pair to the interdomain connecting loop (‘‘hinge’’), it is highly 
probable that the amide is responsible for these interactions (no other H-bond donors in the 
parent benzothiazole molecule, 4). Docking of other active isosteres at this position including 
the nitrile 12, hydroxamate 13, and the hydrazide 16 derivatives confirm the contributions of 
the hinge contacts, and therefore the overall binding mode. Overall, an excellent correlation 
between the interaction energy of this series of benzothiazole N-oxide derivatives and the 
IC50 values was observed and therefore confirms the binding mode that positions C67 for 
nucleophilic attack to form the MC. 
A study has demonstrated that potent and selective inhibitors of protein kinases could be 
obtained using a structural bioinformatics approach that targeted the corresponding cysteine 
described in this work as resulting in specific PLK1 inhibition (Cohen et al., 2005). Sequence 
alignment analysis revealed that eight other protein kinases have the equivalent cysteine 
residue representing four different kinase families. In this example, however, in addition to 
cysteine, a threonine ‘‘gatekeeper’’ was required in order to provide additional space for a 
substituent on the designed inhibitor. While three of these kinases (MSK2, NEK2, and 
RSK1) were probed for inhibition by compounds 4 and 10, and no significant activity 
observed, each could potentially be inhibited by appropriate tuning of the inhibitor containing 
a ‘‘Meisenheimer Complex Scaffold.’’ Furthermore, recent work described the analysis of 
cysteine residues across the human kinome and which would be available for covalent 
inhibitor development (Zhao et al., 2017). This study concluded that there are 44 kinases 
containing cysteine residues that have been successfully exploited by covalent kinase 
inhibitors. There is, therefore, a plethora of potential kinase drug targets that the MC 
approach could be applied to for potent and selective inhibition. While resistance through 
mutation of the cysteine residue is always possible, it remains so regardless of the mode of 
covalent inhibition. 
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In summary, through study of the PLK1 kinase domain, unique features of its ATP binding 
site have been exploited in the discovery and design of inhibitors. A class of PLK1 inhibitors 
based on the benzothiazole N-oxide have been described and shown to selectively inhibit the 
enzyme through an MC, a mechanism of action not previously described for protein kinase 
inhibitors. This pharmacophore represents a prototype for a new approach to generate PLK1 
inhibitors and, in fact, inhibitors in general that possess high selectivity through reversible 
covalent interaction. Such inhibitors have the potential added benefit of minimizing off target 
effects that occur with irreversible inhibitors. 
 
SIGNIFICANCE 
The Polo family of mitotic kinases are clinically validated oncology targets. Structure-based 
discovery and design has led to a class of inhibitors of PLK1 catalytic activity that covalently 
interact with C67 of the ATP binding site. Benzothiazole N-oxide derivatives reversibly 
inhibit PLK1 through the formation of Meisenheimer complexes, a mechanism of kinase 
inhibition, which yields high selectivity while avoiding off target effects that occur through 
covalent binding to other thiol-containing molecules in the cell. Due to recent renewed 
interest in covalently binding inhibitors as a class of drugs, and the plethora of targets that 
can be inhibited using this approach, these compounds represent prototypes for the design of 
kinase inhibitors and, in fact, inhibitors in general that exploit the Meisenheimer complex to 
generate potent and selective compounds that potentially also avoid toxicity issues arising for 
irreversibly binding drugs. 
 
STAR METHODS 
Detailed methods are provided in the online version of this paper and include the following: 
• KEY RESOURCES TABLE 
• CONTACT FOR REAGENT AND RESOURCE SHARING 
• METHOD DETAILS 
o General Method for the Synthesis of 2-alkoxycarbonyl-N-oxide Derivatives 
o Synthesis of 2-Carbamoyl-7-nitro-5-(trifluoromethyl)benzothiazole 3-oxide, 
Compound 4 
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o Synthesis of 4-Fluoro-2,6-dinitrophenyl 4-methylbenzenesulfonate, Precursor 
for Compound 5 
o Synthesis of 2-Carbamoyl-5-fluoro-7-nitrobenzothiazole 3-oxide, Compound 
5 
o Synthesis of 2-Carbamoyl-5-iodo-7-nitrobenzothiazole 3-oxide, Compound 6 
o Synthesis of 2-carbamoyl-5-(methoxycarbonyl)-7-nitrobenzothiazole 3-oxide, 
Compound 7 
o Synthesis of 2-Carbamoyl-5-cyano-7-nitrobenzothiazole 3-oxide, Compound 
8 
o Synthesis of 2-Carbamoyl-5-methyl-7-nitrobenzothiazole 3-oxide , Compound 
9 
o Synthesis of 2-Carbamoyl-7-nitro-5-((trifluoromethyl)thio)benzothiazole 3-
oxide, Compound 10 
o Synthesis of 2-Carbamoyl-5-carboxy-7-nitrobenzothiazole 3-oxide, 
Compound 11 
o Synthesis of 2-Cyano-7-nitro-5-(trifluoromethyl)benzothiazole 3-oxide , 
Compound 12 
o Synthesis of 2-(Hydroxycarbamoyl)-7-nitro-5-(trifluoromethyl)benzothiazole 
3-oxide , Compound 13 
o Synthesis of 2-Carbamoyl-7-nitro-5-(trifluoromethyl)benzothiazole , 
Compound 14 
o Synthesis of 2-Carbamoyl-5-nitro-7-(trifluoromethyl)benzothiazole 3-oxide , 
Compound 15 
o Synthesis of 2-(Hydrazinecarbonyl)-7-nitro-5-(trifluoromethyl)benzothiazole 
3-oxide , Compound 16 
o Expression and Purification of Plk1 for Kinase Assays 
o Construction, Expression and Purification of Cdc25C 
o Procedure for PLK1 Assay 
o Cloning and Expression of PLK1 C67S 
o Procedure for PLK1 and PLK1 C67S Kinase Assay 
o Procedures for Molecular Modeling 
• QUANTIFICATION AND STATISTICAL ANALYSIS 
• DATA AND SOFTWARE AVAILABILITY 
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STAR METHODS 
KEY RESOURCES TABLE 
 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Chemicals, Peptides, and 
Recombinant Proteins 
  
Triethylamine Sigma-Aldrich T0886 
Ethyl thioglycolate Sigma-Aldrich E34307 
Ammonium hydroxide solutions Sigma-Aldrich 338818 
2-Chloro-5-trifluoromethyl-1,3-
dinitrobenzene 
TCI Europe C0994 
4-Fluoro-2,6-dinitrophenol Fisher Scientific 11403557 
2-Chloro-5-iodo-1,3-dinitrobenzene ACES Phamra, 
Inc. 
112587 
2-Chloro-5-methoxycarbonyl-1,3-
dinitrobenzene 
Carbosynth Ltd FM67720 
2-Chloro-5-cyano-1,3-dinitrobenzene Carbosynth Ltd FC70294 
2-Chloro-5-methyl-1,3-dinitrobenzene Sigma-Aldrich PH011654 
2-Chloro-5-(trifluoromethylthio)-1,3-
dinitrobenzene 
NONE Can be synthesized 
according to: Journal of 
Fluorine Chemistry, 125(9), 
1305-1316; 2004 
Sodium hydroxide Sigma-Aldrich 795429 
Phosphorus oxychloride Sigma-Aldrich 262099 
Pyridine Sigma-Aldrich 270970 
Hydroxylamine solution Sigma-Aldrich 467804 
Triethylphosphine Sigma-Aldrich 245275 
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2-Chloro-1,5-dinitro-3-
(trifluoromethyl)benzene 
CambridgeChem 318514052 
Hydrazine solution Sigma-Aldrich 751855 
Sf9 cells in Sf-900TM II SFM ThermoFisher 11496015 
Plk1 open reading frame (X75932) Clontech HA040548 
BL21(DE3)pLysS Chemically 
Competent E. coli 
ThermoFisher C606003 
Critical Commercial Assay   
PLK1 Kinase Assay BPS Bioscineces 
LLC 
PLK1 
Software and Algorithms   
Insight II Biovia Affinity 
PyMol Schrodinger https://pymol.org/2/ 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Campbell McInnes (mcinnes@cop.sc.edu). 
 
METHOD DETAILS 
General Method for the Synthesis of 2-alkoxycarbonyl-N-oxide Derivatives 
See Figure S5 for synthetic scheme (McInnes et al., 2006). Step 1: Triethylamine (1.1 eq) 
was added to a suspension of 5 substituted, 1,3-dinitrobenzyl-2-chloride (1eq) and ethyl 
thioglycolate (1 eq) in ethanol (3 cm3) at 10-20 oC (Supplementary Figure 5.). Onset of the 
reaction was observed by the solvent beginning to reflux even though the mixture was being 
cooled in a water bath. After stirring for a further 3h a precipitate formed which was collected 
by filtration, washed with ice-cold water followed by a further wash with ice-cold methanol. 
Recrystallization from methanol gave the desired ethyl ester derivatives. Step 2: The 2-
alkoxycarbonylbenzothiazol-3-oxide (1 eq) was suspended in ethanol (2 cm3) at 20-30 oC and 
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ammonium hydroxide (1.2 eq) added. After stirring for 4h , the desired 2-carbamoyl 
benzthiazol-3-oxide crystallised from solution, was collected by filtration and was washed 
with ice-cold water and then methanol. Recrystallisation from methanol gave the desired 
amide derivatives. For further information see McInnes et al., 2006. 
 
Synthesis of 2-Carbamoyl-7-nitro-5-(trifluoromethyl)benzothiazole 3-oxide, Compound 
4 
The general method above was followed using 2-chloro-5-trifluoromethyl-1,3 
dinitrobenzene. The title compound was obtained as a yellow crystalline solid: 1H NMR 
(DMSO-d6, 500 MHz): δH 8.76 (2H, s, Ar-H and NH), 8.96 (1H, s, Ar-H) and 9.36 (1H, s, 
NH). MS (ESI+) m/z 308.01 [M+H]+ (C9H5N3O4F3S requires 308.00). mp 222-223 οC (lit 
225-226 οC, Wagner et al., 1973). Anal. RP-HPLC: tR 13.75 min. (10-70% MeCN). 
 
Synthesis of 4-Fluoro-2,6-dinitrophenyl 4-methylbenzenesulfonate, Precursor for 
Compound 5 
4-Fluoro-2,6-dinitrophenol (1 eq) was dissolved in toluene (5 cm3) and tosyl chloride (1.1 eq) 
added followed by pyridine (1.1 eq) (Figure S6). After stirring for 12 h a white precipitate 
formed which was collected by filtration. The mother liquor was evaporated to dryness and 
used without further purification. 1H NMR (DMSO-d6, 500 MHz): δH 2.48 (3H, s, CH3), 7.50 
(2H, d, J 8.0, 2 x Ar-H), 7.67 (2H, d, J 8.0, 2 x Ar-H) and 8.51 (2H, d, J 8.0, 2 x Ar-H). 
 
Synthesis of 2-Carbamoyl-5-fluoro-7-nitrobenzothiazole 3-oxide, Compound 5 
The title compound was obtained as a yellow crystalline solid from 4-fluoro-2,6-
dinitrophenyl 4-methylbenzenesulfonate using the general method for the synthesis of 2-
alkoxycarbonyl-N-oxides. 1H NMR (DMSO-d6, 500 MHz): δH 8.82 (1H, s, NH), 8.88 (1H, d, 
J 7.5, Ar-H), 8.97 (1H, d, J 7.5, Ar-H) and 9.41 (1H, s, NH). C8H5N3O4FS requires M 
257.99848, found 257.99861. mp 282-283 οC. Anal. RP-HPLC: tR 9.83 min. (10-70% 
MeCN). 
 
Synthesis of 2-Carbamoyl-5-iodo-7-nitrobenzothiazole 3-oxide, Compound 6 
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The title compound was obtained as a yellow crystalline solid from 2-chloro-5-iodo-1,3 
dinitrobenzene using the general method. 1H NMR (DMSO-d6, 500 MHz): δH 8.81 (1H, s, 
Ar-H), 8.82 (1H, s, NH), 8.94 (1H, s, Ar-H), and 9.41 (1H, s, NH). C8H4N3O4IS requires M 
364.89673, found 364.89634. 
 
Synthesis of 2-carbamoyl-5-(methoxycarbonyl)-7-nitrobenzothiazole 3-oxide, 
Compound 7 
The title compound was obtained as a yellow crystalline solid from 2-chloro-5 
methoxycarbonyl-1,3-dinitrobenzene using the general method. 1H NMR (DMSO-d6, 300 
MHz): δH 3.89 (3H, s, CH3), 8.78 (4H, s, 2 Ar-H and 2 NH). 
 
Synthesis of 2-Carbamoyl-5-cyano-7-nitrobenzothiazole 3-oxide, Compound 8 
The title compound was obtained as a yellow crystalline solid from 2-chloro-5-cyano-1,3-
dinitrobenzene using the general method. 1H NMR (DMSO-d6, 500 MHz): δH 8.86 (1H, s, 
NH), 9.16 (1H, s, Ar-H), 9.22 (1H, s, Ar-H) and 9.33 (1H, s, NH). C9H4N4O4S requires M 
263.9953, found 263.9951. mp 222-223 οC (lit 225-226 οC, Wagner and Oehlmann., 1976), 
Anal. RP-HPLC: tR 19.60 min. (10-70% MeCN). 
 
Synthesis of 2-Carbamoyl-5-methyl-7-nitrobenzothiazole 3-oxide , Compound 9 
The title compound was obtained as a yellow crystalline solid from 2-chloro-5-methyl-1,3-
dinitrobenzene using the general method. mp 271-272 οC (lit 274-275 οC, Wagner et al., 
1973). Anal. RP-HPLC: tR 11.32 min. (10-70% MeCN). 
 
Synthesis of 2-Carbamoyl-7-nitro-5-((trifluoromethyl)thio)benzothiazole 3-oxide, 
Compound 10 
The title compound was obtained as a yellow crystalline solid from 2-chloro-5-
(trifluoromethylthio)-1,3-dinitrobenzene using the general method. 1H NMR (DMSO-d6, 500 
MHz): δH 8.82 (1H, s, Ar-H), 8.85 (1H, s, Ar-H), 8.90 (1H, s, NH) and 9.35 (1H, s, NH). 
C9H5N3O4F3S2 requires M 339.96736, found 339.96739. mp 255-256 οC, Anal. RP-HPLC: tR 
15.79 min. (10-70% MeCN). 
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Synthesis of 2-Carbamoyl-5-carboxy-7-nitrobenzothiazole 3-oxide, Compound 11 
Compound 7 (26 mg, 0.09 mmol) was suspended in water (1.0 ml) containing methanol (0.1 
ml). Sodium hydroxide (4 mg, 0.1 mmol) in water (0.36 ml) was added and the resultant 
precipitate collected by filtration and washed with water. The title compound was obtained as 
a yellow crystalline solid, 1H NMR (DMSO-d6, 500 MHz): δH 7.88 (1H, s, Ar-H) and 8.35 
(1H, s, Ar-H), C9H5N3O6S requires M 282.9899, found 282.9900. mp 181-183 οC (lit 188-
190 οC, Wagner et al., 1973), tR 16.38 min. (10-70% MeCN). 
 
Synthesis of 2-Cyano-7-nitro-5-(trifluoromethyl)benzothiazole 3-oxide , Compound 12 
Phosphorus oxychloride (306 mg, 0.186 ml, 2.0 mmol) was added to a suspension of 4 (672 
mg, 2.0 mmol) in dry pyridine (1 ml) at 20-30 οC and stirred for 12 h (Wagner and 
Oehlmann., 1976). Ice-water was added and the resultant precipitate collected by filtration. 
The title compound was obtained as a yellow crystalline solid. 1H NMR (DMSO-d6, 500 
MHz): δH 8.91 (1H, s, Ar-H) and 9.02 (1H, s, Ar-H). mp 188-189 οC (lit 190-191 οC, Wagner 
et al., 1973), tR 15.60 min. (10-70% MeCN). 
 
Synthesis of 2-(Hydroxycarbamoyl)-7-nitro-5-(trifluoromethyl)benzothiazole 3-oxide , 
Compound 13 
The title compound was obtained as a yellow crystalline solid from the reaction of compound 
4 with hydroxylamine using routine methodology (Wagner et al., 1973). 1H NMR (DMSO-
d6, 500 MHz): δH 8.86 (1H, s, Ar-H), 8.96 (1H, s, Ar-H), 10.17 and 12.13 (2H, s, NH and 
OH). MS (ESI+) m/z 346.00 [M+Na]+ and 324.07 [M+H]+ (C9H4N3O5F3S requires 322.98). 
mp 230-231 οC (lit 234-235 οC, Wagner et al., 1973). Anal. RP-HPLC: tR 12.33 min. (10-
70% MeCN). 
 
Synthesis of 2-Carbamoyl-7-nitro-5-(trifluoromethyl)benzothiazole , Compound 14 
Compound 4 (30 mg, 0.097 mmol) was dissolved in ethanol (2 ml) and heated to 70 οC. 
Triethyl phosphine (17 mg, 1.1 eq) was added and the mixture remained at 70 οC for a further 
4 h. On cooling the resultant precipitate was collected by filtration. The title compound was 
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obtained as a yellow crystalline solid: 1H NMR (DMSO-d6, 500 MHz): δH 8.36 (1H, s, NH), 
8.68 (1H, s, NH), 8.77 (1H, s, Ar-H) and 8.92 (1H, s, Ar-H). mp 222-224 οC (lit 225-226 οC, 
Wagner and Oehlmann., 1976). Anal. RP-HPLC: tR 16.01 min. (10-70% MeCN). 
 
Synthesis of 2-Carbamoyl-5-nitro-7-(trifluoromethyl)benzothiazole 3-oxide , Compound 
15 
The title compound was obtained as a yellow crystalline solid from 2-chloro-1,5-dinitro-3-
(trifluoromethyl)benzene using the general method. 1H NMR (DMSO-d6, 500 MHz): δH 8.88 
(1H, s, Ar-H), 8.90 (1H, s, NH), 8.97 (1H, s, Ar-H) and 9.33 (1H, s, NH), C9H4F3N3O4S 
requires M 306.9875, found 306.9880. mp 224-225 οC (lit 225-226 οC, Wagner et al., 1973). 
 
Synthesis of 2-(Hydrazinecarbonyl)-7-nitro-5-(trifluoromethyl)benzothiazole 3-oxide , 
Compound 16 
The title compound was obtained as a yellow crystalline solid from the reaction of compound 
4 with hydrazine using standard procedures (Wagner et al., 1973). 1H NMR (DMSO-d6, 500 
MHz): δH 5.20 (2H, s, NH2), 8.88 (1H, s, Ar-H), 8.95 (1H, s, Ar-H) and 11.20 (1H, s, NH). 
mp 229-230 οC (lit 232-233 οC, Wagner et al., 1973). Anal. RP-HPLC: tR 11.88 min. (10-
70% MeCN). 
 
Expression and Purification of Plk1 for Kinase Assays 
The Plk1 open reading frame (X75932) was amplified from a fetal lung complementary DNA 
library (Clontech) using primers incorporating restriction enzyme sites. The 50 primer (5’-
GCCGCTAGCGACGATGACGATAAGATGAGTGCTGCAGTGACTGCAGGGAAGC-3’) 
had an NheI site upstream of the ATG start codon. The 3’ primer (5’-
GGAATTCTTAGGAGGCCTTGAGACGG-3’) incorporated an EcoRI site downstream of 
the stop codon. The PCR product was subcloned into the NheI/EcoRI sites of a baculovirus 
expression vector (pSSP1) derived from pFastBac Hta (Invitrogen). Cloning into this vector 
resulted in a hexahistidine-tag fusion at the N terminus of the Plk1 construct. Sf9 strain cells 
of a passage number less than 20 were split back to give a 300-ml culture volume, at a cell 
density of 1.5 3 106 cells ml_1. Cells were only used for expression in logarithmic growth 
phase. Plk1 baculovirus (from P2 amplification) was added to give a multiplicity of infection 
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of 3; this is equivalent to three virus particles for each insect cell. The flasks were incubated 
at 27 οC, with shaking at 100 r.p.m., for 48 h. On harvest, cell density and viability were 
determined, and the cultures were spun down at 2,500 r.p.m. for 5 min and washed with ice-
cold (0 οC) phosphate-buffered saline. The wash was re-spun at the same speed and the pellet 
was snap frozen. Plk1 protein was purified on a metal affinity column. The insect cell pellet 
was lysed in a buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM β-mercaptoethanol, 1 
mM PMSF, 1 mM benzamidine, 20 mM imidazole and protease inhibitor cocktail (Sigma)) 
and the precleared supernatant was loaded onto Ni-NTA-agarose (Qiagen). The affinity 
column was washed with the lysis buffer and the bound protein was eluted with 250 mM 
imidazole in the same buffer. After overnight dialysis against 25 mM Tris-HCl, pH 7.5, 100 
mM NaCl, 1 mM DTT, 1 mM PMSF, 1 mM benzamidine, protease inhibitor cocktail (Sigma) 
and 10% glycerol, the purified protein was stored at -70 oC until used. 
 
Construction, Expression and Purification of Cdc25C 
Using standard techniques a full-length Cdc25C clone was isolated by PCR from HeLa 
mRNA and inserted on a BamHI-HindIII fragment into the plasmid pRsetA. The N-terminal 
Cdc25C fragment (encoding residues 1–300) was excised from this vector and inserted into 
the plasmid pET28a (between the NcoI and BamHI sites). Expression was under the control 
of the T7 promoter, and the encoded protein contains a hexahistidine tag at the C terminus. 
The vector was transformed into E. coli strain BRL(DE3) pLysS for expression experiments. 
The protein was expressed in BL21(DE3) RIL bacteria cells that were grown in LB medium 
at 37 oC until optical density at 600 nm of 0.6 was reached. Expression was induced with 1 
mM IPTG, and the bacterial culture was grown further for 3 h. The bacteria were harvested 
by centrifugation and the cell pellet resuspended in 50 mM Tris, pH 7.5, and 10% sucrose, 
flash frozen, and stored at -70 oC until used. Purification of the protein was then carried out 
by lysing the bacterial pellet in 10 ml of lysis buffer (10 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, 5 mM β-mercaptoethanol and 20 mM imidazole) supplemented with a cocktail of 
protease inhibitors and sonicated six times at 20-s bursts. The lysate was then centrifuged for 
15 min at 15,000 r.p.m. and filtered through a 0.45-mm filter. The sample was then loaded 
onto a Ni-NTA agarose column and washed several times, and then the Cdc25 protein was 
eluted with a buffer containing 10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM β-
mercaptoethanol, 0.02% Nonidet P-40 (EMD Millipore) and 250 mM imidazole. The eluate 
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was then dialyzed, concentrated, snap frozen in liquid nitrogen and stored at -70 oC until 
used. 
 
Procedure for PLK1 Assay 
PLK1 kinase activity (compounds in Tables 1 and 2) was assayed using either Casein or the 
N-terminal domain of the human Cdc25C phosphatase (a natural substrate for PLK1) as 
substrates. The assays were carried out using a 96-well plate format by incubating Cdc25C (2 
mg/well) or Casein (50 mg/well) with varying concentrations of the Ni-NTA purified PLK1 
and varying concentrations of the negative, non-transformed host Sf9 cell lysate in a total 
volume of 25 ul of 20 mM Tris/HCl buffer pH 7.0, supplemented with 25 mM β-
glycerophosphate, 5 mM EGTA, 1 mM DTT and 1 mM NaVO3. Reaction was initiated by 
the addition of 100 mM ATP and 0.5 mCi of [γ-32P]-ATP. The reaction mixture was 
incubated at 30 oC for 1 h, then stopped with 75 mM aq orthophosphoric acid, transferred 
onto a 96-well P81 filter plate (Whatman), dried, and the extent of Cdc25C phosphorylation 
was assessed by scintillation counting using a Packard TopCount plate reader. 
 
Cloning and Expression of PLK1 C67S 
This was undertaken at BPS Bioscience (San Diego). After C67S mutation and C-terminal 
His tag were introduced by PCR, the insert was cloned into pFastBac vector (Thermo Fisher 
Scientific), followed by sequence analysis. The plasmid was transformed into DH10BacTM. 
E. coli Competent Cells (Thermo Fisher Scientific) where it recombined with the parent 
bacmid to form an expression bacmid. The purified bacmid DNA was tested for 
recombination by PCR. Then the bacmid DNA was transfected into insect cells for 
production of recombinant baculovirus particles. P3 virus was used for protein production. 
Protein was expressed in Sf9 cells using recombinant baculovirus at a MOI of 3 grown in 
SF900II media (Gibco_). Cell were harvest by centrifugation three days after transfection and 
His tagged protein was purified using Ni-NTA affinity. Briefly, cells were lysed by 
sonication after resuspension in TBS-T buffer. Protein was purified using Ni2+-NTA agarose 
(Sigma) eluting with TBS-T buffer plus imidazole. High purity elutions as assessed by SDS 
PAGE were pooled with glycerol and DTT added to a final concentration of 20% and 3 mM 
respectively. Protein was quantified by Bradford reagent (PierceTM) using BSA as the 
standard. Purity was determined to be >90% by SDS PAGE. 
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Procedure for PLK1 and PLK1 C67S Kinase Assay 
For the data shown in Figures 5 and S3, the assay was performed by BPS Bioscience (San 
Diego) using Kinase-Glo Plus luminescence kinase assay kit (obtained from Promega). It 
measures kinase activity by quantitating the amount of ATP remaining in solution following 
a kinase reaction. The luminescent signal from the assay is correlated with the amount of 
ATP present and is inversely correlated with the amount of kinase activity. The compounds 
were diluted in 10% DMSO and 5ml of the dilution was added to a 50 ml reaction so that the 
final concentration of DMSO is 1% in all of reactions. All of the enzymatic reactions were 
conducted at 30 oC for 45 minutes for the wild type PLK1 and 60 min for PLK1(C67S). The 
50 ml reaction mixture contains 40 mM Tris, pH 7.4, 10 mM MgCl2, 0.1 mg/ml BSA, 1 mM 
DTT, 0.1 mg/ml PLK1 peptide substrate, 10 mM (or 5 mM) ATP and PLK1. After the 
enzymatic reaction, 50 ml of Kinase-Glo Plus Luminescence kinase assay solution (Promega) 
was added to each reaction and incubate the plate for 15 minutes at room temperature. The 
luminescence signal was measured using a BioTek Synergy 2 microplate reader. 
 
Procedures for Molecular Modeling 
The homology model for PLK1 was generated using the program module Homology within 
the molecular modelling package InsightII (Accelrys, San Diego, CA) using PKA as a 
template structure. Compounds were docked with the PLK1 homology model using the 
Affinity program within InsightII implementing a molecular dynamics docking routine. The 
binding site was defined as an 8 Å radius from the centre of a ligand placed in the ATP site. 
The calculation was performed using the CVFF force field in a two-step process and an 
implicitly derived solvation model and geometric H-bond restraints. Initially, the inhibitor 
was minimized into the ATP cleft, using a simple non-bonded method where the Coulombic 
and Van der Waals terms are scaled to zero and 0.1, respectively. The refinement phase 
involved molecular dynamics calculated over 5 ps in 100 fs stages, where the temperature 
was scaled from 500 K to 300 K followed by a final minimisation over 1,000 steps using the 
Polak-Ribiere Conjugate Gradient method. The docked structures were ranked energetically 
using the in-house developed programs Calsor and Calsorcont and the Ludi module of 
InsightII. 
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QUANTIFICATION AND STATISTICAL ANALYSIS 
PLK1 activity assays were performed in duplicate at each concentration. The luminescence 
data were analyzed using the computer software, Graphpad Prism. The difference between 
luminescence intensities in the absence of PLK1 (Lut) and in the presence of PLK1 (Luc) 
was defined as 100 % activity (Lut – Luc). Using luminescence signal (Lu) in the presence of 
the compound, % activity was calculated as: 
% activity = {(Lut - Lu)/(Lut - Luc)} x 100%, where Lu= the luminescence intensity in the 
presence of the compound (all percent activities below zero were shown zero in the table). 
The values of % activity versus a series of compound concentrations were then plotted using 
non-linear regression analysis of Sigmoidal dose-response curve generated with the equation 
Y=B+(T-B)/1+10((LogEC50-X)xHill Slope), where Y=percent activity, B=minimum percent 
activity, T=maximum percent activity, X= logarithm of compound and Hill Slope=slope 
factor or Hill coefficient. The IC50 value was determined by the concentration causing a half-
maximal percent activity. 
 
DATA AND SOFTWARE AVAILABILITY 
No data or software beyond what is included in this manuscript and supplementary 
information are available. 
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Table 1. Structure-Activity Relationships for the Benzothiazole N-Oxide PLK1 
Inhibitors 
Compound 
Structure Kinase Inhibition (µM) 
 
R1 R2 R3 R4 PLK1 CDK2/Cyclin 
E 
4 CF3 NO2 CONH2 O 2.47 ± 1.23 > 100 
5 F NO2 CONH2 O 18.1 ± 2.69 > 100 
6 I NO2 CONH2 O 0.36 ± 0.01 > 100 
7 COOCH3 NO2 CONH2 O 7.11 ± 0.86 > 100 
8 CN NO2 CONH2 O 8.4 ± 0.86 44.2 ± 3.18 
9 CH3 NO2 CONH2 O > 100 > 100 
10 SCF3 NO2 CONH2 O 0.39 ± 0.07 > 100 
11 COOH NO2 CONH2 O > 100  
12 CF3 NO2 CN O 17.0 ± 4.24  
13 CF3 NO2 CONHOH O 31.0 ± 15.6 > 100 
14 CF3 NO2 CONH2 - > 100  
15 NO2 CF3 CONH2 O > 100  
16 CF3 NO2 CONHNH2 O > 100  
 
  
S
N
R4
R3
R2
R1
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Table 2. Spectroscopic Results of Benzothiazole N-Oxide Meisenheimer Formation (in 
the Presence of n-BuNH2) 
 
Compounda R1 PLK1 
IC50 
(µM) 
When R3 
= 
CONH2 
δAr1 
(ppm)b 
δAr2 
(ppm)b 
δAr1 
(ppm)b 
+ n-
BuNH2 
δAr2 
(ppm)b + 
n-
BuNH2 
λmax 
(nm), ε 
(L mol-
1 cm-1)c 
λmax 
(nm), ε 
(L mol-1 
cm-1)c + 
n-
BuNH2 
4a CF3 2.47 ± 
1.23 
9.00-
8.99 
8.85-
8.84 
6.78-
6.77 
6.61 405, 
5,369 
440, 
24,832 
5a F 18.1 ± 
2.69 
- - - - 380, 
3,143 
450, 
7,924 
6a I 0.36 ± 
0.01 
8.94 8.81 - - 410, 
3,937 
465, 
12,992 
7a COOCH3 7.11 ± 
0.86 
8.96 8.81 7.10 -7.00 400, 
2,443 
420, 
19,870 
8a CN 8.4 ± 
0.86 
- - - - 410, 
4,399 
450, 
14,076 
9a CH3 > 100 8.65 8.42 8.70-
8.40 
8.70-
8.40 
400, 
5,085 
395, 
5,367 
10a SCF3 0.39 ± 
0.07 
8.93 8.78 6.78 6.64 405, 
4,412 
445, 
18,382 
11a COOH > 100 8.96 8.80 9.00 8.82 395, 
4,063 
390, 
4,375 
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Position C4 of the benzothiazole N-oxide is less hindered, favored by the SNAr mechanism 
and in close proximity to C67 in the docked models. 
aPrimary amide of R3 is replaced by COOEt. 
bAll 1H NMR performed in CDCl3. 
cAll UV-vis in EtOH. 
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Figure 1. Chemical Structures of PLK1 Inhibitory Compounds (2TA, 1; 5TA, 2; and 
adenosine 3) Used in Validation of the Homology Model and for Probing the Covalent 
Modification of the ATP Binding Site 
 
 
 
 
 
 
Figure 2. Complex of 5TA, 2, with the ATP Binding Site of PLK1 
Complex was generated through flexible docking of the free thiol compound into the PLK1 
homology model with selected conformations that correspond to the known binding mode of 
ATP derivatives. The irreversible inhibition of this derivative is supported by the formation 
of the disulfide linkage in silico and minimization of the covalently linked inhibitor. 
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Figure 3. Molecular Docking of the In-Silico-Discovered Benzothiazole N-Oxide, 4, with 
the ATP Binding Site of PLK1 
The binding mode was predicted based on most favorable interaction energies and the SAR 
of the primary amide group is thus consistent with hinge H-bonding interactions. The 
displayed pose is consistent with the Meisenheimer hypothesis requiring the proximity of the 
benzothiazole C4 to the attacking thiol nucleophile from C67. 
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Figure 4. Enzyme Kinetics of Benzothiazole N-Oxide PLK1 Inhibitors 
(A and B) Lineweaver Burk Plot analysis of compounds 4 and 10 suggest that they act via 
competitive (A) and non-competitive (B) binding, respectively. (C) The ATP dependence of 
these two inhibitors further confirms this analysis (compound 4 with red data points and 10 in 
magenta). 
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Figure 5. Comparison of the Activities of Compound 4 (left) and volasertib (right) 
against PLK1 C67S, a Mutant Designed to Test the Contributions to C67 to the Activity 
of the Benzothiazole N-Oxide Series (error bars represent standard deviations 
calculated for duplicate experiments). 
The data obtained for the replacement of the cysteine with a serine, an isosteric residue, and 
which is considerably less nucleophilic, confirms the formation of the Meisenheimer 
complex with 4. 
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Graphical Abstract 
 
 
Far left is the blank (so EtOH)
Second left is compound 10 
(concentration 1.18x10-3M) in 
EtOH.
Second right is compound 10 
(after 10 fold dilution, so 
1.18x10-4M) in EtOH
Far right is compound 10 
(concentration 1.18x10-3M) + 
9eq sodium 1-butanethiolate in 
EtOH
SUPPLEMENTARY FIGURE 1 (related to Table 2).   UV Evidence for Meisenheimer complex with a thiolate nucleophile.
SNF3CS
NO2
O
NH2
O
10
S
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O
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O
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SUPPLEMENTARY FIGURE 2  (Related to Table 2)   UV Trace of addition of sodium  n-butylthiolate to compound 10
Supplementary Figure 3 (Related to Figure 5).   Dose-reponse curve for the inhibition of PLK1 C67S with staurosporine and showing that potent inhibition is retained.
Compound 4
Compound 10
Sub-pocket
Supplementary Figure 4 (Related to Table 1 and Figure 3).   Binding mode of compounds 4 and 10 showing covalent interaction with Cys67. The additional 
interactions of the SCF3 group in 10 are highlighted. 
Cys67
Supplementary Figure 5.  (related to Table1) - Synthetic Scheme for benzthiazole N-oxides  
Supplementary Figure 6 (Related to Table1) Synthesis of Precursor for compound 5. 
Kinase  benzthiazole 4  benzthiazole 10 
Plk1  2.47  0.39 
Cdk2/E  >100  >100 
Cdk2/A  >100  >100 
Cdk1/B  >100  >100 
Cdk4/D1  >100  >100 
Cdk7/H  >100  >100 
Cdk9/T  >100  >100 
CK II  >100  >100 
CamK II  >100  >100 
MAPK2/ERK  >100  >100 
PKC a  >100  >100 
Akt/PKB  >100  >100 
Abl  >100  >100 
GSK3a  >100  >100 
Aurora A  >100  >100 
PKA  >100  >100 
P70S6K  >100  >100 
SAPK2  >100  >100 
Further testing of compound 8 on an additional panel of 20 kinases extented the selectivity 
Supplementary table 1 (Related to Table 1) Kinase Selectivity of Benzthiazoles 4 and 
10 relating to Results section entitled “Kinase Selectivity and Cellular activity of lead 
inhibitors” 
      Enzyme Activity (% of control)
c-RAF 108 ± 10
CDK2/E 88 ± 4
Chk1 111 ± 7
Chk2 97 ± 10
CSK 45 ± 2
FGFR3 83 ± 10
IGF-1R 98 ± 6
IKK 115 ± 14
IR 107±12
JNK22 10 6± 1
MAPKAP-K2 96 ± 11
MEK1 96 ± 6
MKK6 88 ± 5
MSK1 106 ± 5
PDGFR 108 ± 8
PKC 117 ± 15
PKC 82 ± 14
Rsk2 105 ± 5
SAPK2b 94 ± 3
SAPK3 120 ± 6
Yes 108 ± 12
Supplementary Table 2. (Related to Table 1) Screening of compound 4 against a 
panel of 21 kinases from the Millipore Sigma. The percent inhibition of each 
enzyme is reported at 100 µM compound. This table related to Results section 
entitled “Kinase Selectivity and Cellular activity of lead inhibitors”
